Verzenio, also known by its generic name abemaciclib, is a prescription medicine used for certain adults with hormone receptor positive and HER2 negative breast cancer. Its approved uses include some cases of node positive early breast cancer with a high risk of recurrence and certain advanced or metastatic breast cancers.
Verzenio is a CDK4/6 inhibitor used in specific breast cancer treatment settings. According to the current FDA prescribing information, it may be used alone or with endocrine therapy depending on the type and stage of breast cancer and the patient's previous treatment history.
Understanding Verzenio Indications
Verzenio is approved for adults with hormone receptor positive, HER2 negative breast cancer in several specific situations. The appropriate use depends on whether the disease is early, advanced, or metastatic and whether certain treatment criteria are met.
- High risk early breast cancer: Verzenio may be used with endocrine therapy, such as tamoxifen or an aromatase inhibitor, for adults with HR positive, HER2 negative, node positive early breast cancer that has a high risk of recurrence.
- Initial treatment for advanced or metastatic disease: It may be combined with an aromatase inhibitor as initial endocrine based therapy.
- Disease progression after endocrine therapy: Verzenio may be combined with fulvestrant when HR positive, HER2 negative advanced or metastatic breast cancer progresses following endocrine therapy.
- Certain previously treated metastatic disease: Verzenio may be used alone when disease has progressed following endocrine therapy and prior chemotherapy in the metastatic setting.
These indications do not mean Verzenio is appropriate for everyone with breast cancer. Your healthcare professional considers pathology results, lymph node involvement, disease stage, prior treatment, and other individual factors before recommending therapy.
Factors to Discuss With Your Doctor Before Treatment
A detailed discussion with your healthcare team can help determine whether Verzenio fits your treatment plan. It is also important to understand possible adverse effects and monitoring requirements before starting therapy.
- Your cancer characteristics: Ask how hormone receptor and HER2 results, lymph node involvement, and disease stage affect treatment choices.
- Previous treatments: Discuss endocrine therapies, chemotherapy, and other cancer treatments you have received and how they may influence the treatment plan.
- Other medicines: Tell your doctor about prescription medicines, over the counter products, and supplements because some medicines can interact with Verzenio.
- Possible side effects: Diarrhea, neutropenia, nausea, fatigue, infections, anemia, and other adverse reactions can occur. Severe diarrhea can lead to dehydration or infection and should be addressed promptly.
- Monitoring: Ask what blood tests or other monitoring may be needed during treatment and how often your healthcare team will evaluate your response and tolerance.
- Pregnancy and breastfeeding: Discuss pregnancy plans, contraception, and breastfeeding with your healthcare professional because Verzenio has important reproductive safety considerations.
- Dose changes: Your doctor may adjust, interrupt, or discontinue treatment depending on side effects and individual tolerability.
Verzenio has several FDA approved uses for specific adults with HR positive, HER2 negative breast cancer, including certain high risk early, advanced, and metastatic settings. The decision to use it depends on individual cancer characteristics, previous treatments, overall health, and treatment goals. Discussing indications, potential side effects, interactions, monitoring, and reproductive considerations with your doctor can help you better understand your treatment plan. This article is provided for informational purposes only and is not a substitute for personalized medical advice.